The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40425-016-0198-x) contains supplementary material, which is available to authorized users

Metal release and corrosion effects of modular neck total hip arthroplasty

Modular neck implants are an attractive treatment tool in total hip replacement. Concerns remain about the mechanical stability and metal ion release caused by the modular connection. Five different implant designs were investigated in an experimental set-up. In vivo conditions were simulated and the long-term titanium release was measured. Finally, the modular connections were inspected for corrosion processes and signs of fretting. No mechanical failure or excessive corrosion could be identified for the implants tested. The titanium releases measured were extremely low compared to in vivo and in vitro studies and were not in a critical range

Longitudinale Instabilität des Unterarms

The Essex Lopresti lesion is a rare triad of injury to the radial head, interosseous membrane of the forearm and distal radio-ulnar joint, which results in longitudinal instability of the radius. If unrecognized this leads to chronic pain and disability which is difficult to salvage. Early recognition and appropriate treatment is therefore desirable to prevent long-term problems. The aim of this article is to review the pathoanatomy of longitudinal radius instability and use the existing literature and authors’ experience to provide recommendations for recognition and treatment of acute and chronic forearm instability, including description of the author’s technique for interosseous membrane reconstruction.</p

Laser and Light for Wound Healing Stimulation

Understanding wound healing is critical for health care professionals mainly because of the enormous burden of chronic wounds on society. In addition, in many medical specialties, creating wounds for diagnostic and therapeutic purposes is part of a physician’s daily practice. Acute wounds are usually closed using sutures, staples, or other methods of wound closure. Conventional modalities include maintenance of a moist wound bed, and prevention of infection. Although acute wounds are not challenging in most settings, they may influence the hospital stay or expenses related to medical procedures. Chronic wounds however, are more challenging. The incidence of chronic wounds in the United States is approximately five to seven million per year (Sen et al., Wound Repair Regen 17(6):763–771, 2009) and the annual costs for management of these wounds is greater than $20 billion